JP2017510661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510661A5 JP2017510661A5 JP2017504616A JP2017504616A JP2017510661A5 JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5 JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017504616 A JP2017504616 A JP 2017504616A JP 2017510661 A5 JP2017510661 A5 JP 2017510661A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- formula
- antibody
- methyl
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LSHWLXVHVUSFGB-KRLZFLGXSA-N CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O Chemical compound CC[C@H](C)[C@@H](C(N(CC)[C@H](C[C@H](c1nc(C(N[C@H](CC2C(O)=O)Cc(cc3)c2cc3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C2)=O)C2=O)=O)=O)=O)=O)c[s]1)OC(C)=O)C(C)C)=O)NC(C[C@@H]1N(C)CC[C@@H](C)C1)=O LSHWLXVHVUSFGB-KRLZFLGXSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978460P | 2014-04-11 | 2014-04-11 | |
| US61/978,460 | 2014-04-11 | ||
| PCT/US2015/025235 WO2015157594A1 (en) | 2014-04-11 | 2015-04-10 | Tubulysin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510661A JP2017510661A (ja) | 2017-04-13 |
| JP2017510661A5 true JP2017510661A5 (OSRAM) | 2018-05-24 |
Family
ID=54264545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504616A Pending JP2017510661A (ja) | 2014-04-11 | 2015-04-10 | ツブリシン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9427479B2 (OSRAM) |
| EP (1) | EP3129362A4 (OSRAM) |
| JP (1) | JP2017510661A (OSRAM) |
| KR (1) | KR20160142392A (OSRAM) |
| CN (1) | CN106458942A (OSRAM) |
| AR (1) | AR100006A1 (OSRAM) |
| AU (1) | AU2015243379B2 (OSRAM) |
| CA (1) | CA2945318A1 (OSRAM) |
| CL (1) | CL2016002548A1 (OSRAM) |
| EA (1) | EA032203B1 (OSRAM) |
| IL (1) | IL247822A0 (OSRAM) |
| MA (1) | MA39862A (OSRAM) |
| MX (1) | MX2016013373A (OSRAM) |
| NZ (1) | NZ725131A (OSRAM) |
| PH (1) | PH12016501995A1 (OSRAM) |
| SG (1) | SG11201608203RA (OSRAM) |
| TW (1) | TW201625662A (OSRAM) |
| UY (1) | UY36075A (OSRAM) |
| WO (1) | WO2015157594A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
| TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物 |
| PE20180355A1 (es) | 2015-02-25 | 2018-02-21 | Univ Rice William M | Desacetoxitubulisina h y analogos de esta |
| HRP20200882T1 (hr) | 2015-11-10 | 2020-09-04 | Medimmune, Llc | Vezujuće molekule specifične za asct2 i njihova uporaba |
| SG11201804268RA (en) | 2015-12-04 | 2018-06-28 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| CA3012960A1 (en) * | 2016-02-01 | 2017-08-10 | Pfizer Inc. | Tubulysin analogs and methods for their preparation |
| MY198114A (en) | 2016-04-15 | 2023-08-04 | Macrogenics Inc | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| WO2019025983A1 (en) | 2017-08-01 | 2019-02-07 | Medimmune, Llc | CONJUGATED MONOCLONAL ANTIBODY-MEDICINE DIRECTED AGAINST BCMA |
| SG11202004801WA (en) | 2017-12-31 | 2020-06-29 | Hangzhou Dac Biotech Co Ltd | A conjugate of a tubulysin analog with branched linkers |
| CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化（上海）新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
| EP3898651A2 (en) | 2018-12-21 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 |
| JP2022539076A (ja) * | 2019-06-24 | 2022-09-07 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体 |
| JP2023533218A (ja) * | 2020-06-24 | 2023-08-02 | レゲネロン ファーマシューティカルス，インコーポレーテッド | ツブリシン及びタンパク質－ツブリシンコンジュゲート |
| IL301041A (en) | 2020-09-11 | 2023-05-01 | Medimmune Ltd | Therapeutic B7-H4 binding molecules |
| CA3237211A1 (en) | 2021-11-10 | 2023-05-19 | Astrazeneca Ab | Antibody molecules and conjugates |
| GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
| KR20250029133A (ko) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| US20060148014A1 (en) * | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
| IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PT3327027T (pt) * | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| BR112014013526A8 (pt) * | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| SI2956173T1 (sl) * | 2013-02-14 | 2017-06-30 | Bristol-Myers Squibb Company | Spojine tubulizina, postopki pridobivanja in uporaba |
| TW201625662A (zh) * | 2014-04-11 | 2016-07-16 | 麥迪紐有限責任公司 | 妥布賴森（ｔｕｂｕｌｙｓｉｎ）衍生物 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| EP3129055B1 (en) * | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
-
2015
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko not_active Withdrawn
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en not_active Ceased
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510661A5 (OSRAM) | ||
| SA519401072B1 (ar) | Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها | |
| RU2017117664A (ru) | Комбинация | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| NZ604007A (en) | Monoclonal antibodies against her2 epitope | |
| JP2018070648A5 (OSRAM) | ||
| JP2019501204A5 (OSRAM) | ||
| JP2017506227A5 (OSRAM) | ||
| JP2018530554A5 (OSRAM) | ||
| RU2014138474A (ru) | Новые модуляторы и способы применения | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| MY149159A (en) | Method for treating joint damage | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2017506217A5 (OSRAM) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2018512443A5 (OSRAM) | ||
| JP2016523810A5 (OSRAM) | ||
| JP2018504418A5 (OSRAM) | ||
| JP2014530215A5 (OSRAM) | ||
| JOP20210044A1 (ar) | الأجسام المضادة لـ cd38 | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения |